Keyphrases
Riluzole
100%
Advanced Melanoma
100%
Phase II Trial
100%
Melanoma
100%
GRM1
80%
Human Melanoma
40%
Ectopic Expression
20%
Phase 0 Clinical Trials
20%
Melanocytes
20%
Melanocytic Tumor
20%
Mitogen-activated Protein Kinase
10%
Healthy Skin
10%
Tumor Growth
10%
Advanced Disease
10%
Public Health
10%
Animal Experiment
10%
Same Patient
10%
Long-term Toxicity
10%
Blocking Agent
10%
Murine Xenograft Model
10%
Therapeutic Potential
10%
Long-term Administration
10%
Stage IV Melanoma
10%
PET Scan
10%
Durability of Response
10%
Oral Medication
10%
Central Nervous System
10%
Response Rate
10%
Western Blot
10%
Toxic Side Effects
10%
Clinical Response
10%
Melanoma Cells
10%
Science Experiment
10%
Stage III Melanoma
10%
Metabotropic Glutamate Receptor
10%
Murine Model
10%
Molecular Response
10%
Response to Therapy
10%
Medicine and Dentistry
Phase II Trials
100%
Riluzole
100%
Melanoma
100%
Receptor
21%
Ectopic Expression
10%
Melanocyte
10%
Neoplasm
10%
Malignant Neoplasm
5%
Tumor Progression
5%
In Vitro
5%
Mitogen-Activated Protein Kinase
5%
Western Blot
5%
Central Nervous System
5%
Positron Emission Tomography
5%
Side Effect
5%
Blocking Agent
5%
Melanoma Cell
5%
Metabotropic Receptor 1
5%
Upregulation
5%
Xenograft
5%
Diseases
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Phase II Trials
100%
Riluzole
100%
Receptor
20%
Neoplasm
10%
Malignant Neoplasm
5%
Side Effect
5%
Western Blot
5%
Blocking Agent
5%
Tumor Growth
5%
Metabotropic Receptor 1
5%
Polyethylene Terephthalate
5%
Diseases
5%